Christopher Yea - Net Worth and Insider Trading
Christopher Yea Net Worth
The estimated net worth of Christopher Yea is at least $939,866 dollars as of 2024-11-05. Christopher Yea is the CHIEF DEVELOPMENT OFFICER of KalVista Pharmaceuticals Inc and owns about 85,676 shares of KalVista Pharmaceuticals Inc (KALV) stock worth over $939,866. Details can be seen in Christopher Yea's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Christopher Yea has not made any transactions after 2024-08-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Christopher Yea
Christopher Yea Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Christopher Yea owns 1 companies in total, including KalVista Pharmaceuticals Inc (KALV) .
Click here to see the complete history of Christopher Yea’s form 4 insider trades.
Insider Ownership Summary of Christopher Yea
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| KALV | KalVista Pharmaceuticals Inc | 2024-08-23 | Chief Development Officer |
Christopher Yea Latest Holdings Summary
Christopher Yea currently owns a total of 1 stock. Christopher Yea owns 85,676 shares of KalVista Pharmaceuticals Inc (KALV) as of August 23, 2024, with a value of $939,866.
Latest Holdings of Christopher Yea
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KALV | KalVista Pharmaceuticals Inc | 2024-08-23 | 85,676 | 10.97 | 939,866 |
Holding Weightings of Christopher Yea
Christopher Yea Form 4 Trading Tracker
According to the SEC Form 4 filings, Christopher Yea has made a total of 21 transactions in KalVista Pharmaceuticals Inc (KALV) over the past 5 years, including 0 buys and 21 sells. The most-recent trade in KalVista Pharmaceuticals Inc is the sale of 1,916 shares on August 23, 2024, which brought Christopher Yea around $23,758.
Insider Trading History of Christopher Yea
- 1
Christopher Yea Trading Performance
Christopher Yea Ownership Network
Ownership Network List of Christopher Yea
Ownership Network Relation of Christopher Yea
Christopher Yea Owned Company Details
What does KalVista Pharmaceuticals Inc do?
Who are the key executives at KalVista Pharmaceuticals Inc?
Christopher Yea is the Chief Development Officer of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include CFO and Secretary Benjamin L Palleiko , Chief Medical Officer Paul K. Audhya , and Chief Scientific Officer Edward P. Feener .
KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary
Over the past 18 months, Christopher Yea made 8 insider transaction in KalVista Pharmaceuticals Inc (KALV) with a net sale of 89,426. Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net purchase of 1,251,017 shares made by Venrock Healthcare Capital Partners Iii, L.p. , a net sale of 144,760 shares made by Benjamin L Palleiko , and a net sale of 116,267 shares made by Edward P. Feener .
In summary, during the past 3 months, insiders sold 40,693 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 40,693 shares. During the past 18 months, 583,370 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 1,251,017 shares were bought by its insiders, resulting in a net purchase of 667,647 shares.
KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.
KalVista Pharmaceuticals Inc Insider Transactions
Christopher Yea Mailing Address
Above is the net worth, insider trading, and ownership report for Christopher Yea. You might contact Christopher Yea via mailing address: One Kendall Square, Building 200, Suite 2203, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
